Tularaemia - Pipeline Review, H2, Pharmaceutical 2016
"Tularaemia
- Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Tularaemia - Pipeline Review, H2 2016, provides an
overview of the Tularaemia (Infectious Disease) pipeline landscape.
Tularaemia
is an infection caused due to a bacterium called Francisella
tularensis. Humans become infected mainly through the bite of
arthropods, particularly ticks and mosquitoes, and through the skin,
conjunctival sac or oropharyngeal mucosa, by direct contact with
infected animals or animal materials and by ingestion of contaminated
food or water or inhalation of contaminated dust or aerosols.
Symptoms include skin ulcer, swollen and painful lymph glands, fever
and chills. Treatment includes antibiotics and healthy lifestyle.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Tularaemia - Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Tularaemia
(Infectious Disease), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
The
Tularaemia (Infectious Disease) pipeline guide also reviews of key
players involved in therapeutic development for Tularaemia and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II and
Preclinical stages are 2 and 8 respectively. Similarly, the
Universities portfolio in Preclinical and Discovery stages comprises
3 and 1 molecules, respectively.Tularaemia.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Tularaemia (Infectious Disease).
-
The pipeline guide reviews pipeline therapeutics for Tularaemia
(Infectious Disease) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Tularaemia
(Infectious Disease) therapeutics and enlists all their major and
minor projects.
-
The pipeline guide evaluates Tularaemia (Infectious Disease)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Tularaemia (Infectious Disease).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Tularaemia (Infectious Disease) pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Comments
Post a Comment